Reminder on the Use of Dexamethasone
The FDA Advisory No. 1131-20 issued on June 19, 2020, emphasizes that Dexamethasone is a prescription medication that must be used under a physician's supervision. The advisory prohibits the sale of unregistered Dexamethasone or its dispensation without a valid prescription, including through online platforms. Misuse or unsupervised use can lead to serious health risks such as immunosuppression and gastrointestinal issues, among others. The public is urged to report any violations or adverse reactions to the FDA, which will take legal action against offenders.
Law Information
- Reference Number
- FDA Advisory No. 1131-20
- Date Enacted
- Subcategory
- Food and Drugs Administration of the Philippines
- Jurisdiction
- Philippines
- Enacting Body
- Congress of the Philippines
Full Law Text
June 19, 2020
FDA ADVISORY NO. 1131-20
| TO | : | The General Public |
| SUBJECT | : | Reminder on the Use of Dexamethasone |
The Food and Drug Administration (FDA) strongly reminds the public that Dexamethasone is a prescription drug and should strictly be used under the supervision of a licensed physician. There are Dexamethasone products that are currently registered with the FDA. The drug should be only dispensed by licensed establishments to patients with valid prescription. The sale of unregistered Dexamethasone or sale of the drug without valid prescription or through online platforms is strictly prohibited.
Dexamethasone is a steroid drug and is prescribed by a licensed physician based on the patient's medical condition. Misuse or unsupervised chronic use of this drug may lead to serious adverse reactions such as:
• Immunosuppression or impairment of the body's ability to fight infections
• Gastrointestinal bleeding and ulcers
• Electrolyte imbalance
• Osteoporosis
• Muscle weakness
• Poor wound healing
• Prolonged use of the drug may cause suppression of growth among infants and children
• Obesity
If stopped abruptly, it may cause withdrawal symptoms such as hypotension, shock, and coma. 1
All are enjoined to report the dispense and/or use of the drug without a valid prescription to FDA Center for Drug Regulation and Research at [email protected]. For any observed adverse reactions with the use of the drug, seek medical attention immediately and report to the FDA at https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH and fill out all the required fields. All violators shall be dealt with legal actions.
For your guidance. CAIHTE
(SGD.) ROLANDO ENRIQUE D. DOMINGO, MDDirector General
Footnotes
1. https://products.mhra.gov.uk/search/?search=dexamethasone&page=1&doc=Pil.
Cite This Law
Reminder on the Use of Dexamethasone, FDA Advisory No. 1131-20, Jun 19, 2020 (Philippines)
Reminder on the Use of Dexamethasone, FDA Advisory No. 1131-20 (Phil. 2020)
Related Laws
- Paalala sa Publiko Tungkol Paggamit ng DexamethasoneFDA Advisory No. 1131-A-20 • Jun 19, 2020 • Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) Issuances
- Prohibition on the Selling of Essential Emergency Medicines and Medical Devices Beyond the Price Ceiling/Range Set by the Department Memorandum No. 2020-0058FDA Circular No. 017-20 • May 15, 2020 • Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) Issuances
- Baseless Claims of "Prodex-B" as Anti-Viral Treatment for COVID-19FDA Advisory No. 452-20 • Mar 30, 2020 • Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) Issuances
- Reminder on the Strict and Regular Use of the eCourt SystemOCA Circular No. 156-2016 • Jul 18, 2016 • Supreme Court Issuances
- Proper Use of Postal Code Numbers on Mail MattersLetter of Instructions No. 605 • Sep 29, 1977 • Presidential Issuances
- Reminder on the Conduct of Videoconferencing with Respect to Remote Appearance from AbroadOCA Circular No. 144-2023 • Mar 30, 2023 • Supreme Court Issuances
Browse More Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) Issuances
Explore other laws in the Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) Issuances category.
View All Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) IssuancesNeed Help Understanding This Law?
Ask our AI assistant to explain provisions, implications, or related laws.
Ask AI About This Law